2026 ICD-10-CM Diagnosis Code T39.393SPoisoning by other nonsteroidal anti-inflammatory drugs [NSAID], assault, sequela
T39.393S is a billable ICD-10-CM diagnosis code for poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], assault, sequela. The 7th character S marks it as a sequela code, which reports a problem that remains after the original condition has resolved. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 922 through 923. The code is exempt from POA reporting. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Poisoning/toxic effect/adverse effects/underdosing, sequela.
Code Identity
Code Classification
Present on Admission (POA)Billing
T39.393S is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.
Coding GuidelinesGuidance
When coding a poisoning or reaction to the improper use of a medication (e.g., overdose, wrong substance given or taken in error, wrong route of administration), first assign the appropriate code from categories T36-T50. The poisoning codes have an associated intent as their 5th or 6th character (accidental, intentional self-harm, assault and undetermined). If the intent of the poisoning is unknown or unspecified, code the intent as accidental intent. The undetermined intent is only for use if the documentation in the record specifies that the intent cannot be determined. Use additional code(s) for all manifestations of poisonings.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of nonopioid analgesics, antipyretics and antirheumatics (T39). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Diclofenac
a non-steroidal anti-inflammatory agent (nsaid) with antipyretic and analgesic actions. it is primarily available as the sodium salt.Etodolac
a non-steroidal anti-inflammatory agent and cyclooxygenase-2 (cox-2) inhibitor with potent analgesic and anti-arthritic properties. it has been shown to be effective in the treatment of osteoarthritis; rheumatoid arthritis; ankylosing spondylitis; and in the alleviation of postoperative pain (pain, postoperative).Flufenamic Acid
an anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. it is used in musculoskeletal and joint disorders and administered by mouth and topically. (from martindale, the extra pharmacopoeia, 30th ed, p16)Indomethacin
a non-steroidal anti-inflammatory agent (nsaid) that inhibits cyclooxygenase, which is necessary for the formation of prostaglandins and other autacoids. it also inhibits the motility of polymorphonuclear leukocytes.Meclofenamic Acid
a non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. it also inhibits prostaglandin biosynthesis.Mefenamic Acid
a non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. it is an inhibitor of cyclooxygenase.Nabumetone
a butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (cox2) inhibitor that is used in the management of pain associated with osteoarthritis and rheumatoid arthritis.Piroxicam
a cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (nsaid) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. its long half-life enables it to be administered once daily.Sulindac
a sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active nsaid analgesic. specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. this helps to maintain constant blood levels with reduced gastrointestinal side effects.Tolmetin
a non-steroidal anti-inflammatory agent (anti-inflammatory agents, non-steroidal) similar in mode of action to indomethacin.
Table of Drugs and ChemicalsClinical
Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.
Patient EducationClinical
Pain Relievers
Pain relievers are medicines that reduce or relieve headaches, sore muscles, arthritis, or other aches and pains. There are many different pain medicines, and each with advantages and risks. Some types of pain respond better to certain medicines than others. Each person may also have a slightly different response to a pain reliever.
The full article covers:
- What are pain relievers?
- What are the types of over-the-counter pain relievers?
- What are prescription pain relievers?
- What are some non-drug treatments for pain?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert T39.393S to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About T39.393SOverview
Is T39.393S a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], assault, sequela on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character S in T39.393S mean?
The final character S makes this a sequela code: it reports a lingering problem that remains after the poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], assault itself has resolved, not the original event.
What MS-DRG does T39.393S group to?
When poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], assault, sequela is the principal diagnosis on an inpatient stay, it groups to MS-DRG 922, 923, with relative weights from 1.0177 to 1.7494 depending on complications. Higher weights mean higher Medicare reimbursement.
Is T39.393S exempt from POA reporting?
Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], assault, sequela on inpatient claims.
What is the ICD-9 equivalent of T39.393S?
Under the General Equivalence Mappings, poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], assault, sequela converts to ICD-9-CM 909.0 (late eff drug poisoning) and E969 (late effect assault). The mapping is approximate, so confirm the match fits the documentation.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
